24/7 Market News Snapshot 16 July, 2025 – OKYO Pharma Limited Ordinary Shares (NASDAQ:OKYO)

DENVER, Colo., 16 July, 2025 (www.247marketnews.com) – (NASDAQ:OKYO) are discussed in this article.
OKYO Pharma Limited is currently witnessing a notable fluctuation in its stock performance, with ordinary shares opening at $2.83 but recently trading at $2.545, marking a decline of approximately 7.45%. This downturn follows a previous session close of $2.750 and points to a potential bearish sentiment among investors, likely triggered by profit-taking or concerns surrounding the company’s near-term outlook. Current trading volume is reported at 759.45K, indicating significant market activity. Analysts are advised to monitor key support levels around $2.50; a breach could invite further selling pressure, while a rebound above $2.75 may signal a revival in bullish momentum. Upcoming news and earnings reports will be pivotal in shaping market sentiment.

Simultaneously, OKYO Pharma has made substantial strides in its development of Urgosimod, a novel treatment aimed at neuropathic corneal pain (NCP). Preliminary results from a Phase 2 clinical trial involving 18 participants reveal that 75% of those treated with a 0.05% formulation of Urgosimod experienced over an 80% reduction in pain, as measured by Visual Analogue Scale (VAS) scores. This advancement is particularly significant given the absence of an FDA-approved therapy for NCP.

The randomized, double-masked, placebo-controlled trial exhibited statistically significant reductions in pain scores, with improvements evident as early as Week 4 and maintained through the study duration. Dr. Pedram Hamrah, the principal investigator, emphasized the implications of these findings, indicating a breakthrough treatment for individuals suffering from moderate to severe NCP.

Dr. Gary S. Jacob, CEO of OKYO, praised the trial outcomes and underscored the company’s commitment to bringing Urgosimod to market. Plans are underway for a discussion with the FDA regarding the next steps, marking a strategic move in advancing clinical development to address this critical medical need effectively. The growing interest in Urgosimod positions OKYO as a frontrunner in developing effective therapies for chronic neuropathic pain.

Related news for (OKYO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.